Arbutus Biopharma Corp Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)
Arbutus Biopharma Corp (ABUS) reported Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-16.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 · last filed 2018-03-16
- Arbutus Biopharma Corp noncash or part noncash acquisition, net nonmonetary assets acquired (liabilities assumed) for the quarter ending 2016-12-31 was $0.00.
- Arbutus Biopharma Corp noncash or part noncash acquisition, net nonmonetary assets acquired (liabilities assumed) for the quarter ending 2016-09-30 was $0.00.
- Arbutus Biopharma Corp noncash or part noncash acquisition, net nonmonetary assets acquired (liabilities assumed) for the quarter ending 2016-06-30 was $0.00.
- Arbutus Biopharma Corp noncash or part noncash acquisition, net nonmonetary assets acquired (liabilities assumed) for the quarter ending 2016-03-31 was $0.00, a 100.00% decline year-over-year.
- Arbutus Biopharma Corp noncash or part noncash acquisition, net nonmonetary assets acquired (liabilities assumed) for fiscal 2017 was $0.00.
- Arbutus Biopharma Corp noncash or part noncash acquisition, net nonmonetary assets acquired (liabilities assumed) for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- Arbutus Biopharma Corp noncash or part noncash acquisition, net nonmonetary assets acquired (liabilities assumed) for fiscal 2015 was $381.62M.
- Arbutus Biopharma Corp noncash or part noncash acquisition, net nonmonetary assets acquired (liabilities assumed) for fiscal 2014 was $0.00.
| Period end | Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) 3 month | Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) 6 month | Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) 9 month | Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-03-16 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $0.00 derived: sum of 2 quarters · filed 2018-03-16 | $0.00 derived: sum of 3 quarters · filed 2018-03-16 | $0.00 10-K · filed 2018-03-16 |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-03 | $0.00 derived: sum of 2 quarters · filed 2016-11-03 | $0.00 10-Q · filed 2016-11-03 | $0.00 derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-04 | $0.00 10-Q · filed 2016-08-04 | $0.00 derived: sum of 3 quarters · filed 2018-03-16 | $0.00 derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-04 | $0.00 derived: sum of 2 quarters · filed 2018-03-16 | $0.00 derived: sum of 3 quarters · filed 2018-03-16 | $0.00 derived: sum of 4 quarters · filed 2018-03-16 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $0.00 derived: sum of 2 quarters · filed 2018-03-16 | $0.00 derived: sum of 3 quarters · filed 2018-03-16 | $381.62M 10-K · filed 2018-03-16 |
| 2015-09-30 | $0.00 10-Q · filed 2016-11-03 | $0.00 derived: sum of 2 quarters · filed 2016-11-03 | $381.62M 10-Q · filed 2016-11-03 | $381.62M derived: sum of 4 quarters · filed 2017-03-22 |
| 2015-06-30 | $0.00 10-Q · filed 2016-08-04 | $381.62M 10-Q · filed 2016-08-04 | $381.62M derived: sum of 3 quarters · filed 2017-03-22 | $381.62M derived: sum of 4 quarters · filed 2017-03-22 |
| 2015-03-31 | $381.62M 10-Q · filed 2016-05-04 | $381.62M derived: sum of 2 quarters · filed 2017-03-22 | $381.62M derived: sum of 3 quarters · filed 2017-03-22 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-22 | $0.00 derived: sum of 2 quarters · filed 2017-03-22 | $0.00 10-K · filed 2017-03-22 | |
| 2014-09-30 | $0.00 10-Q · filed 2015-11-05 | $0.00 10-Q · filed 2015-11-05 | ||
| 2013-12-31 | $0.00 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |